Validation Data Gallery
|Positive WB detected in||HepG2 cells, human liver tissue, mouse liver tissue, rat liver tissue|
|Positive IP detected in||mouse liver tissue|
|Positive IHC detected in||rat liver tissue, human liver cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||human liver cancer tissue, rat liver tissue|
|Positive FC detected in||HepG2 cells|
|Western Blot (WB)||WB : 1:5000-1:50000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:1000-1:4000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:1000-1:4000|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
11739-1-AP targets ASGR1 in WB, IP, IHC, IF, FC, CoIP, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||ASGR1 fusion protein Ag2310|
|Full Name||asialoglycoprotein receptor 1|
|Calculated molecular weight||291 aa, 33 kDa|
|Observed molecular weight||40 kDa|
|GenBank accession number||BC032130|
|Gene ID (NCBI)||432|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
Asialoglycoprotein receptor (ASGPR), also known as the hepatic galactose/N-acetylglucosamine (GlcNAc) receptor or Ashwell receptor, is a C-type lectin expressed exclusively in hepatic parenchymal cells. ASGPR consists of two subunits, a major subunit (ASGR1, HL-1) and a minor subunit (ASGR2, HL-2), and specifically recognizes terminal β-linked galactose or GlcNAc on circulating glycoproteins or cells. This receptor plays a critical role in serum glycoprotein homeostasis by mediating the endocytosis and lysosomal degradation of glycoproteins that contain terminal galactose or GlcNAc residues. ASGPR may facilitate hepatic infection by multiple viruses including hepatitis B, and is also a target for liver-specific drug delivery.
|Product Specific Protocols|
|WB protocol for ASGR1 antibody 11739-1-AP||Download protocol|
|IHC protocol for ASGR1 antibody 11739-1-AP||Download protocol|
|IF protocol for ASGR1 antibody 11739-1-AP||Download protocol|
|IP protocol for ASGR1 antibody 11739-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Regulated control of gene therapies by drug-induced splicing.
A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo.
Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply.
Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy.
ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth.
Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
James (Verified Customer) (11-18-2022)
Very good antibody! Used it to label hepatocytes in section of paraffin-embedded liver tissue